干扰素-γ释放作为接受免疫检查点抑制剂治疗的非小细胞肺癌患者的生物标志物的水平。
The Levels of Interferon-gamma Release as a Biomarker for Non-small-cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
机构信息
Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan
Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.
出版信息
Anticancer Res. 2019 Nov;39(11):6231-6240. doi: 10.21873/anticanres.13832.
BACKGROUND/AIM: The present study aimed to prospectively examine the usefulness of interferon-gamma (IFN-γ) release (IGR) as a biomarker in non-small-cell lung cancer patients receiving immune checkpoint inhibitor treatment (ICI-Tx).
PATIENTS AND METHODS
IGR was measured using enzyme-linked immunosorbent assay at four time points: within 14 days before ICI-Tx (T1), and 8±3 (T2), 22±7 (T3), and 43±7 (T4) days after ICI-Tx.
RESULTS
Twenty-nine patients were divided into three groups based on IFN-γ levels in the IGR-positive control: Group-1 (n=8) with <10 IU/ml at T1, Group-2 (n=12) with a decrease in IFN-γ levels to <10 IU/ml at T3 and/or T4, and Group-3 (n=9) without changes in IFN-γ levels. Early progression and ICI-induced interstitial pneumonitis were frequently observed in Group-1 and Group-2, respectively. Group-3 exhibited more treatment cycles than the other groups. All three groups showed clear differences in clinical outcomes.
CONCLUSION
IFN-γ levels could be a biomarker for ICI-Tx.
背景/目的：本研究旨在前瞻性评估干扰素-γ（IFN-γ）释放（IGR）作为接受免疫检查点抑制剂治疗（ICI-Tx）的非小细胞肺癌患者的生物标志物的有用性。
患者和方法
IGR 使用酶联免疫吸附测定法在四个时间点进行测量：ICI-Tx 前 14 天内（T1），以及 ICI-Tx 后 8±3 天（T2）、22±7 天（T3）和 43±7 天（T4）。
结果
根据 IGR 阳性对照中 IFN-γ 水平，将 29 名患者分为三组：组 1（n=8）在 T1 时 IFN-γ<10 IU/ml，组 2（n=12）在 T3 和/或 T4 时 IFN-γ 水平下降至<10 IU/ml，组 3（n=9）IFN-γ 水平无变化。分别在组 1 和组 2 中观察到早期进展和 ICI 诱导的间质性肺炎。组 3 的治疗周期比其他组多。三组的临床结局均有明显差异。
结论
IFN-γ 水平可能是 ICI-Tx 的生物标志物。
Zotero 插件